# QLH12016

Source: https://onco.cc/drugs/qlh12016/  
OnCo record `qlh12016` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

QLH12016 is an experimental protein degrader from Qilu Pharmaceutical in phase 2 trials for prostate cancer, aimed at Androgen receptor.

## Summary

QLH12016 is a protein degrader developed by Qilu Pharmaceutical. Its target is Androgen receptor. ClinicalTrials.gov describes the intervention as: An oral androgen receptor PROTAC; QLH12016 will be administered orally at the dose and dosing frequency specified in the protocol. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in prostate cancer. The largest, NCT07198633, plans to enrol 212 participants with primary completion expected 2026-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: protein degrader
- Mechanism: Protein degrader directed at Androgen receptor, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

## Sources

- ClinicalTrials.gov: trials of QLH12016: https://clinicaltrials.gov/search?intr=QLH12016
- Sponsor page: https://www.qilu-pharma.com

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- targets: [Androgen receptor](https://onco.cc/targets/androgen-receptor/)
- companies: [Qilu Pharmaceutical](https://onco.cc/companies/qilu-pharmaceutical/)
- trials: [A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer](https://onco.cc/trials/nct07198633/)

---
JSON: https://onco.cc/api/v1/entities/qlh12016.json